ZA200202905B - Formulation of substituted benzimidazoles. - Google Patents

Formulation of substituted benzimidazoles. Download PDF

Info

Publication number
ZA200202905B
ZA200202905B ZA200202905A ZA200202905A ZA200202905B ZA 200202905 B ZA200202905 B ZA 200202905B ZA 200202905 A ZA200202905 A ZA 200202905A ZA 200202905 A ZA200202905 A ZA 200202905A ZA 200202905 B ZA200202905 B ZA 200202905B
Authority
ZA
South Africa
Prior art keywords
sodium
liquid formulation
stable liquid
potassium salt
formulation according
Prior art date
Application number
ZA200202905A
Other languages
English (en)
Inventor
Mikael Bruells
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200202905B publication Critical patent/ZA200202905B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200202905A 1999-10-22 2002-04-12 Formulation of substituted benzimidazoles. ZA200202905B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9903831A SE9903831D0 (sv) 1999-10-22 1999-10-22 Formulation of substituted benzimidazoles

Publications (1)

Publication Number Publication Date
ZA200202905B true ZA200202905B (en) 2003-07-14

Family

ID=20417464

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202905A ZA200202905B (en) 1999-10-22 2002-04-12 Formulation of substituted benzimidazoles.

Country Status (36)

Country Link
US (1) US6730685B1 (es)
EP (1) EP1274427B1 (es)
JP (1) JP2003512327A (es)
KR (1) KR100785603B1 (es)
CN (1) CN1213751C (es)
AR (1) AR029005A1 (es)
AT (1) ATE304851T1 (es)
AU (1) AU782866B2 (es)
BG (1) BG65580B1 (es)
BR (1) BR0014895A (es)
CA (1) CA2425199C (es)
CO (1) CO5261533A1 (es)
CY (1) CY1106055T1 (es)
CZ (1) CZ20021375A3 (es)
DE (1) DE60022789T2 (es)
DK (1) DK1274427T3 (es)
EE (1) EE05175B1 (es)
ES (1) ES2246903T3 (es)
HK (1) HK1051142A1 (es)
HU (1) HUP0203121A3 (es)
IL (2) IL149107A0 (es)
IS (1) IS2196B (es)
MX (1) MXPA02003900A (es)
MY (1) MY131971A (es)
NO (1) NO329545B1 (es)
NZ (1) NZ518155A (es)
PL (1) PL199868B1 (es)
RU (1) RU2286782C2 (es)
SE (1) SE9903831D0 (es)
SI (1) SI1274427T1 (es)
SK (1) SK286266B6 (es)
TR (1) TR200201103T2 (es)
TW (1) TWI236372B (es)
UA (1) UA74347C2 (es)
WO (1) WO2001028558A1 (es)
ZA (1) ZA200202905B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271182B2 (en) * 2000-08-04 2007-09-18 Takeda Pharmaceutical Company Limited Salts of benzimidazole compound and use thereof
WO2002015908A1 (fr) * 2000-08-18 2002-02-28 Takeda Chemical Industries, Ltd. Injections
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CA2512928A1 (en) * 2003-02-24 2004-09-02 Mitsubishi Pharma Corporation The enantiomer of tenatoprazole and the use thereof in therapy
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
US20060089376A1 (en) * 2004-10-27 2006-04-27 Joshi Ramesh A Tenatoprazole salts and process of preparation thereof
EP2018151A4 (en) * 2006-05-09 2012-07-18 Astrazeneca Ab PARENTERAL FORMULATION COMPRISING AN INHIBITOR OF THE PROTON PUMP STERILIZED IN ITS FINAL CONTAINER BY IONIZING RADIATION
CN100411613C (zh) * 2006-12-08 2008-08-20 中国药科大学 一种奥美拉唑速释固体制剂及其制备方法
JP6698651B2 (ja) 2014-11-13 2020-05-27 スリーエム イノベイティブ プロパティズ カンパニー 試料中の細菌atpを検出するためのatp−ジホスホヒドロラーゼを含むキット
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
DK399389A (da) * 1988-08-18 1990-02-19 Takeda Chemical Industries Ltd Injicerbare oploesninger
JP2536173B2 (ja) * 1988-08-18 1996-09-18 武田薬品工業株式会社 注射剤
KR930000861B1 (ko) 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
DK0652751T3 (da) 1992-07-28 1996-11-18 Astra Ab Injektionspræparat og injektions-kit indeholdende omeprazol og dens analoger
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
TW359614B (en) 1993-08-31 1999-06-01 Takeda Chemical Industries Ltd Composition containing benzimidazole compounds for rectal administration
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
US6287594B1 (en) * 1998-01-20 2001-09-11 Edward S. Wilson Oral liquid compositions

Also Published As

Publication number Publication date
EP1274427A1 (en) 2003-01-15
CN1213751C (zh) 2005-08-10
HUP0203121A2 (hu) 2003-01-28
JP2003512327A (ja) 2003-04-02
SK5392002A3 (en) 2002-10-08
MY131971A (en) 2007-09-28
ATE304851T1 (de) 2005-10-15
TWI236372B (en) 2005-07-21
AR029005A1 (es) 2003-06-04
KR100785603B1 (ko) 2007-12-14
IL149107A (en) 2008-04-13
BG106602A (en) 2002-12-29
IL149107A0 (en) 2002-11-10
MXPA02003900A (es) 2002-09-30
SE9903831D0 (sv) 1999-10-22
IS2196B (is) 2007-01-15
US6730685B1 (en) 2004-05-04
NO20021860L (no) 2002-05-21
PL354926A1 (en) 2004-03-22
AU1182301A (en) 2001-04-30
EP1274427B1 (en) 2005-09-21
SI1274427T1 (sl) 2006-02-28
HK1051142A1 (en) 2003-07-25
BR0014895A (pt) 2002-06-18
CY1106055T1 (el) 2011-04-06
CZ20021375A3 (cs) 2002-09-11
ES2246903T3 (es) 2006-03-01
RU2286782C2 (ru) 2006-11-10
HUP0203121A3 (en) 2004-01-28
DK1274427T3 (da) 2005-12-27
EE05175B1 (et) 2009-06-15
BG65580B1 (bg) 2009-01-30
PL199868B1 (pl) 2008-11-28
DE60022789D1 (de) 2006-02-02
DE60022789T2 (de) 2006-06-22
NZ518155A (en) 2004-07-30
AU782866B2 (en) 2005-09-01
NO20021860D0 (no) 2002-04-19
EE200200204A (et) 2003-04-15
IS6347A (is) 2002-04-17
CA2425199A1 (en) 2001-04-26
SK286266B6 (sk) 2008-06-06
CO5261533A1 (es) 2003-03-31
NO329545B1 (no) 2010-11-08
CA2425199C (en) 2010-12-07
WO2001028558A1 (en) 2001-04-26
CN1382048A (zh) 2002-11-27
KR20020059637A (ko) 2002-07-13
TR200201103T2 (tr) 2002-08-21
UA74347C2 (uk) 2005-12-15

Similar Documents

Publication Publication Date Title
ZA200202905B (en) Formulation of substituted benzimidazoles.
KR100258423B1 (ko) 오메프라졸 및 그의 동족체를 함유하는 주사제 및 주사제 키트
US5536735A (en) Pharmaceutical composition
SK6062003A3 (en) Freeze-dried pantoprazole preparation and pantoprazole injection
JPWO2006134877A1 (ja) 注射剤
JP6923122B2 (ja) 難溶性複合物又はその溶媒和物、薬物組成物及びその応用
ES2232459T3 (es) Derivados de benzimidazol antiulcerosos estables frente a los acidos de administracion oral.
JPH0576929B2 (es)
SK51298A3 (en) Pharmaceutical compositions containing platelet aggregation inhibitors
CN101497603B (zh) 含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
CN101497604B (zh) 含有被烷氧乙酰胺基氧基取代的吡啶的苯并咪唑衍生物
CN101492461A (zh) 含烷氧乙基取代的吡啶并四氢异噁唑的苯并咪唑衍生物
JPH07157440A (ja) 医薬用組成物
CN101492462A (zh) 含有异噁唑并吡啶的苯并咪唑衍生物